[go: up one dir, main page]

CO2019011980A2 - Formas cristalinas de (s)-afoxolaner - Google Patents

Formas cristalinas de (s)-afoxolaner

Info

Publication number
CO2019011980A2
CO2019011980A2 CONC2019/0011980A CO2019011980A CO2019011980A2 CO 2019011980 A2 CO2019011980 A2 CO 2019011980A2 CO 2019011980 A CO2019011980 A CO 2019011980A CO 2019011980 A2 CO2019011980 A2 CO 2019011980A2
Authority
CO
Colombia
Prior art keywords
crystalline forms
afoxolaner
crystalline
compositions
compound
Prior art date
Application number
CONC2019/0011980A
Other languages
English (en)
Inventor
De Vries Roelof Johannes Gorter
Bruno Baillon
Sylvaine Lafont
De Saint Michel Myriam Gay
Stephane Kozlovic
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of CO2019011980A2 publication Critical patent/CO2019011980A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Secondary Cells (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

RESUMEN Formas cristalinas del compuesto de fórmula (Ia) y procesos de elaboración de las formas cristalinas. También se proveen composiciones que comprenden las formas cristalinas y métodos de uso de dichas formas cristalinas. (Ia)
CONC2019/0011980A 2017-04-05 2019-10-28 Formas cristalinas de (s)-afoxolaner CO2019011980A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (1)

Publication Number Publication Date
CO2019011980A2 true CO2019011980A2 (es) 2020-02-18

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011980A CO2019011980A2 (es) 2017-04-05 2019-10-28 Formas cristalinas de (s)-afoxolaner

Country Status (22)

Country Link
US (2) US10662163B2 (es)
EP (1) EP3606911A1 (es)
JP (1) JP7222909B2 (es)
KR (1) KR102612648B1 (es)
CN (2) CN120172925A (es)
AR (1) AR111412A1 (es)
AU (1) AU2018250304B2 (es)
CA (1) CA3059114A1 (es)
CL (1) CL2019002840A1 (es)
CO (1) CO2019011980A2 (es)
EA (1) EA201992360A1 (es)
IL (1) IL269792B (es)
MD (1) MD20190080A2 (es)
MX (1) MX2019011931A (es)
MY (1) MY188420A (es)
PH (1) PH12019502277A1 (es)
SG (1) SG11201909229SA (es)
TW (1) TWI782976B (es)
UA (1) UA125727C2 (es)
UY (2) UY37665A (es)
WO (1) WO2018187623A1 (es)
ZA (1) ZA201906464B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102612648B1 (ko) * 2017-04-05 2023-12-11 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 (s)-아폭솔라너의 결정질 형태
CN115768753B (zh) * 2020-06-19 2024-04-26 东莞市东阳光动物保健药品有限公司 一种gaba抑制剂的晶型及其制备方法
JP7724845B2 (ja) 2020-07-24 2025-08-18 エランコ・ユーエス・インコーポレイテッド イソオキサゾリン化合物及びその中間体を作製するための方法
CN118536571B (zh) * 2024-05-31 2025-02-25 北京无问芯穹科技有限公司 一种构建扩散变换器模型的方法、系统、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI600639B (zh) 2007-08-17 2017-10-01 杜邦股份有限公司 製備５-鹵烷基-４，５-二氫異唑衍生物之化合物
MX2012013758A (es) 2010-05-27 2013-01-24 Du Pont Forma cristalina de 4-[5-[3-cloro-5-trifluorometil)fenil]-4,5-dihi dro-5-(trifluorometil)-3-isoxazolil]-n-[2-oxo-2-[(2,2,2-trifluoro etil)amino]etil]-1-naftalenocarboxamida.
PH12018501647A1 (en) * 2011-09-12 2019-02-27 Merial Inc Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
BR112017021073A2 (pt) * 2015-04-08 2018-07-03 Merial Inc composições injetáveis de liberação prolongada compreendendo um agente ativo de isoxazolina, seus métodos e usos
PL3978483T3 (pl) 2016-04-06 2025-03-24 Boehringer Ingelheim Vetmedica Gmbh Krystaliczny solwat toluenowy (S)-afoksolaneru
KR102612648B1 (ko) * 2017-04-05 2023-12-11 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 (s)-아폭솔라너의 결정질 형태

Also Published As

Publication number Publication date
AU2018250304A1 (en) 2019-10-31
AU2018250304B2 (en) 2022-03-03
CA3059114A1 (en) 2018-10-11
CN111032634B (zh) 2025-04-11
US20200270219A1 (en) 2020-08-27
TW201841895A (zh) 2018-12-01
US10662163B2 (en) 2020-05-26
CL2019002840A1 (es) 2020-01-10
BR112019021072A2 (pt) 2020-05-12
KR20190136055A (ko) 2019-12-09
MD20190080A2 (ro) 2020-04-30
UA125727C2 (uk) 2022-05-25
CN111032634A (zh) 2020-04-17
UY40794A (es) 2024-07-15
EA201992360A1 (ru) 2020-09-02
KR102612648B1 (ko) 2023-12-11
MX2019011931A (es) 2020-01-13
JP2020513010A (ja) 2020-04-30
SG11201909229SA (en) 2019-11-28
UY37665A (es) 2018-10-31
EP3606911A1 (en) 2020-02-12
US11130739B2 (en) 2021-09-28
MY188420A (en) 2021-12-08
US20180354917A1 (en) 2018-12-13
WO2018187623A8 (en) 2019-10-24
AR111412A1 (es) 2019-07-10
NZ757869A (en) 2024-11-29
IL269792B (en) 2022-04-01
PH12019502277A1 (en) 2020-09-14
JP7222909B2 (ja) 2023-02-15
WO2018187623A1 (en) 2018-10-11
ZA201906464B (en) 2021-08-25
TWI782976B (zh) 2022-11-11
IL269792A (en) 2019-11-28
CN120172925A (zh) 2025-06-20

Similar Documents

Publication Publication Date Title
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
SV2017005467A (es) Formas sólidas de un inhibidor ask1.
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
CO2019006687A2 (es) Polimorfos
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO2019006673A2 (es) Polimorfos
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CL2017000540A1 (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.
MX2017015315A (es) Granos de gluten reducido y composiciones de los mismos.
NI202000042A (es) Polimorfos
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.